Antibe Therapeutics (STU:4B70) Institutional Ownership: 0.59% (As of Aug. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:4B70 Antibe Therapeutics Inc STU:4B70
10 GF Score
Price €2.44
View Full Analysis

What is Antibe Therapeutics Institutional Ownership?

Antibe Therapeutics STU:4B70 10 Institutional Ownership is 0.59% as of Aug. 18, 2026. GuruFocus rates STU:4B70 with a GF Score™ of 10/100.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Antibe Therapeutics's institutional ownership is 0.59%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Antibe Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Antibe Therapeutics's Float Percentage Of Total Shares Outstanding is 0.00%.

Antibe Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Antibe Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Antibe Therapeutics Institutional Ownership Chart

Antibe Therapeutics Historical Data

The historical data trend for Antibe Therapeutics can be seen below:

2021-12-31 2022-01-31 2022-02-28 2022-03-31 2022-04-30 2022-05-31 2022-06-30 2022-07-31 2022-08-31 2022-09-30
Institutional Ownership 0.59 0.59 0.59 0.59 0.59 0.59 0.59 0.59 0.59 0.59
STU:4B70
10GF Score
Antibe Therapeutics Inc STU:4B70
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Antibe Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.59% mean?
Antibe Therapeutics (STU:4B70) has a Institutional Ownership of 0.59% as of Aug. 18, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Antibe Therapeutics and its competitors.
Is Antibe Therapeutics' Institutional Ownership too high?
Antibe Therapeutics' current Institutional Ownership is 0.59%. Overall, Antibe Therapeutics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Antibe Therapeutics' Institutional Ownership compare to VRTX and REGN?
Antibe Therapeutics' Institutional Ownership of 0.59% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Antibe Therapeutics and its competitors. Antibe Therapeutics's current Institutional Ownership is 0.59%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Antibe Therapeutics stock overvalued right now?
Antibe Therapeutics (STU:4B70) has a current Institutional Ownership of 0.59%. The current Institutional Ownership is 0.59%. Antibe Therapeutics' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Antibe Therapeutics (STU:4B70), the current Institutional Ownership is 0.59% as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Antibe Therapeutics Business Description

Address 15 Prince Arthur Avenue, Toronto, ON, CAN, M5R 1B2
Antibe Therapeutics Inc is a clinical stage biotechnology company leveraging its proprietary hydrogen sulfide (H2S) platform to develop next-generation therapies to address inflammation arising from a wide range of medical conditions. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Antibe's drug, otenaproxesul, is in development for the treatment of acute and chronic pain. The company's second pipeline drug is a GI-sparing alternative to ketoprofen. The company's next target is inflammatory bowel disease (IBD), a condition long in need of safer, more effective therapies.
10GF Score

Get the complete analysis for STU:4B70

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.44
Price